AstraZeneca Results Presentation Deck
BioPharmaceuticals: Respiratory & Immunology
Total Revenue ($m)
800
700
600
500
400
300
200
100
0
EM
EROW
■ Europe
■US
Q3
151
96
155
274
Symbicort
1% decrease at CER to $1,842m in 9M 2023
2021
Q4
152
96
171
262
Q1
167
91
157
259
Q2
139
98
155
222
2022
Q3
169
91
133
237
Q4
133
95
137
255
44 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World.
Q1
229
79
147
233
Q2
2023
177
86
137
200
Q3
195
81
123
156
300
250
200
150
100
50
☐EM
0
EROW
■ Europe
■US
Q3
173
12
15
17
Pulmicort
10% growth at CER to $493m in 9M 2023
11
2021
Q4
193
13
23
19
Q1
164
13
18
22
Q2
72
12
17
15
2022
APPENDIX | 9M 2023 Product Performance
Q3
103
12
14
16
-
Q4
123
12
19
12
Q1
182
9
20
10
Q2
2023
90
11
16
7
Q3
119
11
13
5View entire presentation